{"id":2603,"date":"2026-10-01T13:30:00","date_gmt":"2026-10-01T13:30:00","guid":{"rendered":"https:\/\/i360news.wpenginepowered.com\/?p=2603"},"modified":"2026-09-30T19:38:04","modified_gmt":"2026-09-30T19:38:04","slug":"cloverleaf-bio-has-filed-a-notice-of-an-exempt-offering-of-securities-to-raise-29599977-00-in-new-funding","status":"publish","type":"post","link":"https:\/\/intelligence360.news\/cloverleaf-bio-has-filed-a-notice-of-an-exempt-offering-of-securities-to-raise-29599977-00-in-new-funding\/","title":{"rendered":"Cloverleaf Bio has filed a notice of an exempt offering of securities to raise $29,599,977.00 in New Funding."},"content":{"rendered":"\n

According to filings with the U.S. Securities and Exchange Commission, Cloverleaf Bio is raising up to $29,599,977.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.<\/p>\n\n\n\n

About Cloverleaf Bio
Cloverleaf Bio is a developer of a Ribonucleic Acid (RNA) therapeutics development platform designed to revolutionize cancer therapy and patient outcomes in oncology. The company’s platform allows for direct inhibition of various enzymes necessary for cancer growth from a single therapeutic molecule, enabling engineered tRNA therapeutics to improve patient outcomes in oncology.<\/p>\n\n\n\n

To learn more, visit https:\/\/cloverleafbio.com\/<\/a>
LinkedIn: https:\/\/www.linkedin.com\/company\/cloverleaf-bio\/<\/a><\/p>\n\n\n\n

Contact:
Austin Draycott, President
https:\/\/www.linkedin.com\/in\/austin-draycott\/<\/a><\/p>\n\n\n\n

SOURCE: http:\/\/www.intelligence360.io<\/a>
Copyright (c) 2026 SI360 Inc. All rights reserved.<\/p>\n","protected":false},"excerpt":{"rendered":"

According to filings with the U.S. Securities and Exchange Commission, Cloverleaf Bio is raising up to $29,599,977.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation […]<\/p>\n","protected":false},"author":1,"featured_media":2604,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[50],"tags":[329,327,272,42,328,330,97],"class_list":["post-2603","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-vc","tag-329","tag-cloverleaf-bio","tag-connecticut","tag-intelligence360","tag-new-haven","tag-new-haven-meriden","tag-venture-capital"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t